Diagnosis requires a combination of clinical performance, imaging, laboratory testing, and pathological activation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnoses and treatment plans. Treatment and management of antigenase III deficiency treatments require individualized development, typically including drug therapy, rehabilitation interventions, regular follow-up visits, etc.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of antigenase III deficiency.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.